Amanda‐Louise Fenger Carlander

Rigshospitalet

Papers

1

Total Citations

10

H-Index

1

About

Amanda-Louise Fenger Carlander is a leading surgical oncologist whose research centers on the treatment of oropharyngeal squamous cell carcinoma (OPSCC), with a particular focus on advancing transoral robotic surgery (TORS). Her major contribution lies in demonstrating that TORS, combined with neck dissection, can achieve excellent oncologic outcomes for early-stage OPSCC while dramatically reducing the need for adjuvant radiotherapy or chemoradiotherapy. Her landmark 2024 study, which has already garnered 10 citations, prospectively followed a consecutive single-institution cohort and showed that patients could avoid the significant long-term toxicities of radiation—such as dysphagia and xerostomia—without compromising survival. This work directly challenges the prevailing paradigm of primary radiotherapy for HPV-positive OPSCC and provides compelling evidence for a surgery-first approach in carefully selected patients. By quantifying low rates of adjuvant therapy and excellent functional outcomes, Carlander has provided the data needed to shift clinical practice toward less morbid treatment pathways. Her research is particularly impactful for young, HPV-positive patients who stand to benefit most from avoiding radiation’s lifelong side effects.

Research Focus

Key Achievements

1
H-Index
1
Papers
10
Total Citations
10
Avg Citations/Paper
🏆 Most Cited Paper
Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020
10 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 10
🏛 Institutions: Rigshospitalet

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago